- Home
- ORIS vs CRVO Comparison
ORIS vs CRVO Comparison
Compare ORIS & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIS
- CRVO
- Stock Information
- Founded
- ORIS 2014
- CRVO 2001
- Country
- ORIS China
- CRVO United States
- Employees
- ORIS N/A
- CRVO N/A
- Industry
- ORIS Farming/Seeds/Milling
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- ORIS Consumer Staples
- CRVO Health Care
- Exchange
- ORIS Nasdaq
- CRVO Nasdaq
- Market Cap
- ORIS 182.0M
- CRVO 160.4M
- IPO Year
- ORIS 2024
- CRVO N/A
- Fundamental
- Price
- ORIS $6.41
- CRVO $9.58
- Analyst Decision
- ORIS
- CRVO Strong Buy
- Analyst Count
- ORIS 0
- CRVO 6
- Target Price
- ORIS N/A
- CRVO $53.67
- AVG Volume (30 Days)
- ORIS 212.0K
- CRVO 78.8K
- Earning Date
- ORIS 12-03-2024
- CRVO 11-12-2024
- Dividend Yield
- ORIS N/A
- CRVO N/A
- EPS Growth
- ORIS N/A
- CRVO N/A
- EPS
- ORIS 0.96
- CRVO N/A
- Revenue
- ORIS $24,122,000.00
- CRVO $10,066,550.00
- Revenue This Year
- ORIS N/A
- CRVO $54.67
- Revenue Next Year
- ORIS N/A
- CRVO N/A
- P/E Ratio
- ORIS $7.02
- CRVO N/A
- Revenue Growth
- ORIS N/A
- CRVO 116.29
- 52 Week Low
- ORIS $4.80
- CRVO $5.85
- 52 Week High
- ORIS $11.75
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- ORIS N/A
- CRVO 27.48
- Support Level
- ORIS N/A
- CRVO $9.31
- Resistance Level
- ORIS N/A
- CRVO $11.44
- Average True Range (ATR)
- ORIS 0.00
- CRVO 0.90
- MACD
- ORIS 0.00
- CRVO -0.23
- Stochastic Oscillator
- ORIS 0.00
- CRVO 6.34
About ORIS Oriental Rise Holdings Limited Ordinary Shares
Oriental Rise Holdings Ltd is a company who is an integrated supplier of tea products in Mainland China. Their major tea products include primarily-processed tea consisting of white tea and black tea, and refined white tea and black tea. Its business operations are vertically integrated, covering cultivation, processing of tea leaves and the sale of tea products to tea business operators (such as wholesale distributors) and end-user retail customers in Mainland China.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.